Get the Stockscreener App
206.69
0.98%
2.01
After Hours:
206.06
-0.63
-0.30%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $206.69, with a volume of 4.38M.
It is up +0.98% in the last 24 hours and up +10.89% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$204.68
Open:
$205.91
24h Volume:
4.38M
Relative Volume:
0.76
Market Cap:
$365.13B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
98.42
EPS:
2.1
Net Cash Flow:
$18.24B
1W Performance:
+4.36%
1M Performance:
+10.89%
6M Performance:
+7.17%
1Y Performance:
+6.87%
1-Day Range:
$204.32
$206.84
1-Week Range:
$196.89
$206.84
52-Week Range:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
206.69 | 361.58B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
701.23 | 613.56B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.64 | 420.78B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
124.21 | 236.35B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.21 | 206.72B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Insider Moves: Microsoft, AMD, Boeing, AbbVie, Eli Lilly - TipRanks
AbbVie, Dow, Kratos, Rocket, Applied Materials: Trending by Analysts - TipRanks
Stock Analysis | Abbvie OutlookNavigating Mixed Signals Amid Analyst Optimism - AInvest
AbbVie's Key RICO Claims In Drug Cost Fraud Suit Survive - Law360
AbbVie’s Ubrogepant Study: A Potential Game-Changer for Pediatric Migraine Treatment - TipRanks
Pfizer and AbbVie Advance Pediatric Antibiotic Study: Market Implications - TipRanks
AbbVie’s Promising Phase 2 Study on Metastatic Colorectal Cancer Treatment - TipRanks
AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer - TipRanks
AbbVie’s Promising Phase 1 Trial for Cancer Treatment: A Closer Look - TipRanks
AbbVie’s Promising Phase 3 Study on Etentamig for Multiple Myeloma - TipRanks
Stephen Hahn steps down as CEO of Flagship biotech; A new era at AbbVie partner Gubra - Endpoints News
ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Newsfile
AbbVie to invest $195M to build plant in Illinois - MSN
AbbVie’s Promising Phase 3 Study on Upadacitinib for Takayasu Arteritis - TipRanks
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Stocks Generating Improved Relative Strength: AbbVie - MSN
AbbVie’s Promising Gene Therapy for Wet AMD: A Game Changer? - TipRanks
AbbVie’s ABBV-453 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Vitiligo - TipRanks
Glenmark Pharma's Strategic Global Expansion and Revenue Catalysts: A Deep Dive into Long-Term Growth and Immediate Opportunities - AInvest
Will AbbVie Inc. benefit from macro trendsWeekly Trend Report & Weekly Setup with ROI Potential - Newser
Abbvie Surges 1.42% on $195M Expansion as $0.72B Trading Volume Ranks 165th - AInvest
AbbVie to Invest $195 Million in US API Manufacturing - PharmTech
AbbVie to invest $195 million in US drug ingredient manufacturing - The American Bazaar
AbbVie (ABBV) Invests US$195 Million To Expand U.S. Pharmaceutical Production - Yahoo Finance
AbbVie shares rise 1.06% intraday after announcing a $195 million investment in Illinois manufacturing facility. - AInvest
AbbVie’s Innovative Approach to NSCLC Treatment: A New Clinical Study Update - The Globe and Mail
AbbVie to build API plant in Illinois as it steps up US production - BioPharma Dive
Cantor Fitzgerald raises Abbvie stock price target to $215 on strong Skyrizi performance - Investing.com Canada
AbbVie to invest $195m in new API production facility in US - World Pharmaceutical Frontiers
AbbVie Injects $195 Million Into US Active Pharmaceutical Ingredient Manufacturing - Powder & Bulk Solids
AbbVie investing $195 million in API manufacturing facility - The Pharma Letter
AbbVie expands North Chicago API production with $195m investment - Pharmaceutical Technology
AbbVie invests $195M to expand API manufacturing capabilities - Serrari Group
5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call - Yahoo Finance
$195M AbbVie Expansion Boosts Illinois Pharma Industry - Business Facilities
Technical signs of recovery in AbbVie Inc.IPO Watch & Free Fast Entry Momentum Trade Alerts - Newser
AbbVie Invests $195 Million in US API Production - CHEManager
With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight - insights.citeline.com
Illinois secures AbbVie’s $195 million investment for North Chicago facility - MSN
AbbVie To Invest $195 Mln In Illinois API Manufacturing Expansion - Nasdaq
C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Novartis, Apollomics Inc., Abbvie, Janssen Research and Developm - Barchart.com
AbbVie's Q2 2025 Earnings Reaffirm Gilgamesh Acquisition's Potential - AInvest
AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition (NYSE:ABBV) - Seeking Alpha
AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients - Yahoo Finance
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
AbbVie details nearly $200M API plant as part of new US investments - Endpoints News
AbbVie to invest $195M in North Chicago manufacturing expansion - The Business Journals
AbbVie Invests $195 Million to Expand US API Manufacturing Capabilities. - AInvest
AbbVie to invest $195M to build plant in Illinois (ABBV:NYSE) - Seeking Alpha
AbbVie investing $195 million to expand manufacturing footprint in Illinois - Daily Herald
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):